Modulating epigenetic modifications for cancer therapy (Review)

Leonardo Josué Castro-Muñoz; Elenaé Vázquez Ulloa; Cecilia Sahlgren; Marcela Lizano; Erick De La Cruz-Hernández; Adriana Contreras-Paredes

doi:10.3892/or.2023.8496

Modulating epigenetic modifications for cancer therapy (Review)

Leonardo Josué Castro-Muñoz, Elenaé Vázquez Ulloa, Cecilia Sahlgren, Marcela Lizano, Erick De La Cruz-Hernández, Adriana Contreras-Paredes

Research output: Contribution to journal › Review Article or Literature Review › peer-review

55 Citations (Scopus)

157 Downloads (Pure)

Abstract

Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non‑coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA‑based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer.

Original language	English
Article number	59
Journal	Oncology Reports
Volume	49
Issue number	3
DOIs	https://doi.org/10.3892/or.2023.8496
Publication status	Published - Mar 2023
MoE publication type	A2 Review article in a scientific journal

Keywords

Humans
Epigenesis, Genetic
DNA Methylation
Neoplasms/drug therapy
RNA, Untranslated/metabolism
Carcinogenesis/genetics

Access to Document

10.3892/or.2023.8496

2023 Modulating epigenetic modifications for cancer therapy (Review) (Castro-Muñoz et al., Oncol Rep)Final published version, 965 KBLicence: CC BY-NC-ND

https://urn.fi/URN:NBN:fi-fe2023050139735

Notch counteracts replication stress to prevent cancer cell senescence
Sahlgren, C. (Principal Investigator)
Cancer Foundation Finland, Sigrid Jusélius Foundation
01/05/20 → 31/12/23
Project: Foundation
CellMech: Center of Excellence in Cellular Mechanostasis
Sahlgren, C. (Principal Investigator), Sistonen, L. (Principal Investigator), Eriksson, J. (Principal Investigator), Toivola, D. (Principal Investigator), Meinander, A. (Principal Investigator), Cheng, F. (Principal Investigator) & Jacquemet, G. (Principal Investigator)
01/03/19 → 29/02/24
Project: Foundation

Cite this

@article{82594557d6b0433aa35cb2e2c3572f93,

title = "Modulating epigenetic modifications for cancer therapy (Review)",

abstract = "Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non‑coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA‑based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer.",

keywords = "Humans, Epigenesis, Genetic, DNA Methylation, Neoplasms/drug therapy, RNA, Untranslated/metabolism, Carcinogenesis/genetics",

author = "Castro-Mu{\~n}oz, {Leonardo Josu{\'e}} and Ulloa, {Elena{\'e} V{\'a}zquez} and Cecilia Sahlgren and Marcela Lizano and {De La Cruz-Hern{\'a}ndez}, Erick and Adriana Contreras-Paredes",

year = "2023",

month = mar,

doi = "10.3892/or.2023.8496",

language = "English",

volume = "49",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "3",

}

TY - JOUR

T1 - Modulating epigenetic modifications for cancer therapy (Review)

AU - Castro-Muñoz, Leonardo Josué

AU - Ulloa, Elenaé Vázquez

AU - Sahlgren, Cecilia

AU - Lizano, Marcela

AU - De La Cruz-Hernández, Erick

AU - Contreras-Paredes, Adriana

PY - 2023/3

Y1 - 2023/3

N2 - Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non‑coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA‑based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer.

AB - Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non‑coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA‑based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer.

KW - Humans

KW - Epigenesis, Genetic

KW - DNA Methylation

KW - Neoplasms/drug therapy

KW - RNA, Untranslated/metabolism

KW - Carcinogenesis/genetics

U2 - 10.3892/or.2023.8496

DO - 10.3892/or.2023.8496

M3 - Review Article or Literature Review

C2 - 36799181

SN - 1021-335X

VL - 49

JO - Oncology Reports

JF - Oncology Reports

IS - 3

M1 - 59

ER -

Modulating epigenetic modifications for cancer therapy (Review)

Abstract

Keywords

Access to Document

Fingerprint

Projects

Notch counteracts replication stress to prevent cancer cell senescence

CellMech: Center of Excellence in Cellular Mechanostasis

Cite this